Prior to joining the company, Dr. Go held senior positions of increasing responsibility at Amgen, most recently as U.S. medical lead for Vectibix, medical director in Global Development. Dr. Go has co-authored 25 peer-reviewed articles and presentation abstracts.
Mr. Aycock has more than 17 years of drug development experience investigating a broad range of oncology candidates in pediatric and adult settings. Mr. Aycock previously held roles of increasing responsibility during his 13 years at Amgen, where he led the Kepivance and Nplate development programs. Most recently he served as director of Oncology Study Management & U.S. Regional Lead, overseeing five oncology programs.
"I am delighted to announce the additions of Will Go and Jeff Aycock, each of whom brings a distinguished track record in oncology R&D within leadership roles at Amgen," said Arie Belldegrun, M.D., Kite's president and chief executive officer. "These hires continue the momentum in expanding our clinical development team, which has included the recent appointments of Dr. Jeff Wiezorek as vice president of Clinical Development and of Dr. David Chang as our new chief medical officer."